2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carboxylic acids: Novel 5-HT3 receptor antagonists with anxiolytic-like activity in rodent behavioral models

被引:9
作者
Mahesh, Radhakrishnan [1 ]
Dhar, Arghya Kusum [1 ]
Jindal, Ankur [1 ]
Bhatt, Shvetank [1 ]
机构
[1] Birla Inst Technol & Sci, Dept Pharm, Pilani 333031, Rajasthan, India
关键词
5-HT3; antagonist; anxiolytic; 1; 8-naphthyridine; L/D; EPM; OFT; ELEVATED PLUS-MAZE; ANIMAL-MODELS; ANXIETY DISORDERS; HIGHLY POTENT; PHARMACOLOGY; VALIDATION; DEPRESSION; APPARATUS; TARGET; DRUGS;
D O I
10.1139/cjpp-2013-0134
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to investigate the anxiolytic potential of a series of novel carboxylic acid based 1,8 naphthyridines as 5-HT3 receptor antagonists. The pA(2) values of all the compounds were determined against agonist 2-methyl-5-hydroxytryptamine in longitudinal muscle myenteric plexus preparations from guinea pig ileum. Compounds with higher pA(2) values, particularly those greater than ondansetron, a standard 5-HT3 receptor antagonist, and optimal log P values were screened in mice by using behavioral tests such as a light-dark (L/D) aversion test, elevated plus maze (EPM) test, and an open field test (OFT). In the L/D test, compounds 7a, 7b, 7d, 7e, and 7i (2 mg/kg body mass, intraperitoneal) significantly (P < 0.05) increased the latency time to leave the light compartment, total time spent in the light compartment, and the number of transitions between the light and dark compartments. Compounds 7a, 7d, 7f, 7h, and 7i (2 mg/kg, i.p.) significantly (P < 0.05) increased the time spent in the open arms and the number of entries into the open arms in the EPM test. In addition, compounds 7a, 7d, 7e, 7f, and 7h (2 mg/kg, i.p.) significantly (P < 0.05) increased the ambulation scores and the frequency of rearing in the OFT.
引用
收藏
页码:848 / 854
页数:7
相关论文
共 62 条
[1]   ELECTROPHYSIOLOGY OF THE CENTRAL SEROTONIN SYSTEM - RECEPTOR SUBTYPES AND TRANSDUCER MECHANISMS [J].
AGHAJANIAN, GK ;
SPROUSE, JS ;
SHELDON, P ;
RASMUSSEN, K .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 600 :93-103
[2]   Neuropsychological functions in anxiety disorders in population-based samples: evidence of episodic memory dysfunction [J].
Airaksinen, E ;
Larsson, M ;
Forsell, Y .
JOURNAL OF PSYCHIATRIC RESEARCH, 2005, 39 (02) :207-214
[3]   THE PHARMACOLOGY OF VA21B7 - AN ATYPICAL 5-HT3 RECEPTOR ANTAGONIST WITH ANXIOLYTIC-LIKE PROPERTIES IN ANIMAL-MODELS [J].
ARTAIZ, I ;
ROMERO, G ;
ZAZPE, A ;
MONGE, A ;
CALDERO, JM ;
ROCA, J ;
LASHERAS, B ;
DELRIO, J .
PSYCHOPHARMACOLOGY, 1995, 117 (02) :137-148
[4]   Identification of somatic and anxiety symptoms to the detection of depression in primary which contribute health care [J].
Barkow, K ;
Heun, R ;
Üstün, TB ;
Berger, M ;
Bermejo, I ;
Gaebel, W ;
Härter, W ;
Schneider, F ;
Stieglitz, RD ;
Maier, W .
EUROPEAN PSYCHIATRY, 2004, 19 (05) :250-257
[5]   BEHAVIORAL PHARMACOLOGY OF 5-HT3-RECEPTOR LIGANDS [J].
BARNES, JM ;
BARNES, NM ;
COOPER, SJ .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1992, 16 (01) :107-113
[6]   ANXIOGENIC EFFECTS OF METHYL-BETA-CARBOLINE-3-CARBOXYLATE IN A LIGHT DARK CHOICE SITUATION [J].
BELZUNG, C ;
MISSLIN, R ;
VOGEL, E ;
DODD, RH ;
CHAPOUTHIER, G .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1987, 28 (01) :29-33
[7]   Calcium channel antagonists suppress cross-tolerance to the anxiogenic effects of D-amphetamine and nicotine in the mouse elevated plus maze test [J].
Biala, Grazyna ;
Kruk, Marta .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2008, 32 (01) :54-61
[8]   BRL-46470A - A HIGHLY POTENT, SELECTIVE AND LONG-ACTING 5-HT(3) RECEPTOR ANTAGONIST WITH ANXIOLYTIC-LIKE PROPERTIES [J].
BLACKBURN, TP ;
BAXTER, GS ;
KENNETT, GA ;
KING, FD ;
PIPER, DC ;
SANGER, GJ ;
THOMAS, DR ;
UPTON, N ;
WOOD, MD .
PSYCHOPHARMACOLOGY, 1993, 110 (03) :257-264
[9]   Do animal models of anxiety predict anxiolytic-like effects of antidepressants? [J].
Borsini, F ;
Podhorna, J ;
Marazziti, D .
PSYCHOPHARMACOLOGY, 2002, 163 (02) :121-141
[10]   A MODEL TO MEASURE ANTICIPATORY ANXIETY IN MICE [J].
BORSINI, F ;
LECCI, A ;
VOLTERRA, G ;
MELI, A .
PSYCHOPHARMACOLOGY, 1989, 98 (02) :207-211